CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 28, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, announces a landmark development for global healthcare innovation, His Highness Sheikh Nahyan bin Zayed Al Nahyan, Chairman of the Zayed Charitable and Humanitarian Foundation, will formally assume the role of Executive Chairman of Nu ...

I focus on producing objective, data-driven research, mostly about small- to mid-cap companies, as these tend to be overlooked by many investors. From time to time, though, I also look at large-cap names, just to give a fuller sense of the broader equity markets.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in ...

CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 09, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, has announced two major strategic developments that solidify its expansion into the Middle East. Its wholly owned subsidiary, NuroMENA Holdings Ltd., has signed a Master Services Agreement (MSA) with Insights Research Organization and ...

Core Insights - New to The Street is set to broadcast a nationwide episode on Fox Business featuring interviews with innovative companies such as NeOnc Technologies, FLOKI, XION, Sharps Technology, and Aeries Technology, focusing on their growth and leadership in their sectors [1][2]. Group 1: Company Highlights - The episode will showcase NeOnc Technologies (NASDAQ:NTHI), FLOKI, XION, Sharps Technology (NASDAQ:STSS), and Aeries Technology (NASDAQ:AERT), emphasizing their innovations and market positions [1]. - New to The Street aims to spotlight cutting-edge companies and emerging leaders through investor-focused interviews [2]. Group 2: Programming and Reach - The broadcast is presented as sponsored programming, supported by national TV commercials, enhancing visibility for featured companies [3]. - New to The Street has been a premier platform for corporate storytelling for over 16 years, providing exposure on Fox Business and Bloomberg TV, and has a significant digital presence with over 3.5 million YouTube subscribers [4].

CALABASAS, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced a significant milestone in its partnership with Quazar Investment. Following the receipt of all necessary tax identification and regulatory approvals from the United Arab Emirates (UAE), the closing of the previously announced $50 million strategic partn ...

CALABASAS, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced it has appointed Dr. David M. Ashley to its scientific advisory board. Dr. Ashley is the Rory David Deutsch Distinguished Professor of Neuro-Oncology and the Director of The Preston Robert Tisch Brain Tumor Center at Duke University. Amir F. Heshmatpour ...

Core Insights - NeOnc Technologies Holdings, Inc. has appointed Dr. Alexandra M. Miller to its scientific advisory board, enhancing its expertise in neuro-oncology [2][3] - Dr. Miller's background in developing liquid biopsy assays for CNS tumors will support NeOnc's clinical trials for its therapeutics NEO100™ and NEO212™ [3][4] - The company is expanding its global trial network, with new sites opening in the Middle East and India, indicating growth in its research capabilities [4] Company Overview - NeOnc Technologies is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system cancers, particularly addressing challenges related to the blood-brain barrier [6] - The company's NEO™ drug development platform has produced a portfolio of novel drug candidates, with patent protections extending to 2038 [6] - NEO100™ and NEO212™ are currently in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status [6]

CALABASAS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced it has appointed Dr. Henry S. Friedman to its scientific advisory board. Dr. Friedman is an internationally renowned academic adult and pediatric neuro-oncologist who helps to lead The Preston Robert Tisch Brain Tumor Center at Duke University. He is th ...

NeOnc Technologies to Showcase Progress on Addressing Brain Cancer to 63 Million TV Households on “Health Uncensored with Dr. Drew" on the Lifetime Network on September 25, premiering nationwide at 8:00 a.m. ET/PT Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies, and Dr. Thomas Chen, CEO and Chief Medical Officer, will sit down with Dr. Drew—who earned his medical degree from the University of Southern California (USC)—to explain NeOnc’s platform technology. CALABASAS, Calif., S ...

CALABASAS, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced that the U.S. Food and Drug Administration (FDA) has authorized the Company to proceed with Phase IIa/IIb of its NEO212-01 clinical trial. The FDA’s decision follows the successful completion of the Phase I dose-escalation study, which demonstra ...